

December 25, 2024

J-Pharma Co., Ltd.

Announcement of presentation at the J.P. Morgan Healthcare Conference 2025

J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO: Masuhiro Yoshitake) will be making a presentation at the 43rd J.P. Morgan Healthcare Conference, which will be held from January 13 to January 16, 2025. Only a few unlisted Japanese biotech ventures are selected to present at this conference every year. J-Pharma is honored to be presenting for five consecutive years. Information on the conference is noted below:

J-Pharma is moving forward with plans to initiate a global Phase 3 study of our lead compound, nanvuranlat, for the second-line treatment of biliary tract cancer in 2025. J-Pharma also plans to initiate three other clinical trials in the same year to test the value of LAT1 inhibitors. In this presentation, we will discuss the aims and progress of these clinical programs.

In addition to the presentation, J-Pharma leadership team members will be available for one-on-one meetings with investors, industry partners, and other stakeholders throughout the Conference.

1. Date and Time: Wednesday January 16, 2025 10:00 – 10:25 (U.S. Pacific Time)
2. Venue: San Francisco, California, U.S.A.
3. Presenter: Mr. Yutaka Fujimoto, Director & CFO
4. Meeting Request

CONTACT: <https://www.j-pharma.com/en/contact>

[For further information, please contact.]

J-Pharma Co., Ltd.,
Administration Department, Public Relations
TEL: 045-506-1155
FAX: 045-506-1156
Mail: info@j-pharma.com